ANP Technologies company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

anptinc.com

Founded Year

2002

About ANP Technologies

ANP Technologies specializes in the areas of bio-defense, therapeutics, immunogenicity testing, and pesticide and toxin detection based on Nano-Intelligent technology.

ANP Technologies Headquarter Location

824 Interchange Blvd.

Newark, Delaware, 19711,

United States

302-283-1730

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

ANP Technologies Patents

ANP Technologies has filed 22 patents.

The 3 most popular patent topics include:

  • Polymers
  • Mitotic inhibitors
  • Taxanes
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/21/2017

6/23/2020

Antineoplastic drugs, Organochlorides, Alkylating antineoplastic agents, Topoisomerase inhibitors, Prodrugs

Grant

Application Date

11/21/2017

Grant Date

6/23/2020

Title

Related Topics

Antineoplastic drugs, Organochlorides, Alkylating antineoplastic agents, Topoisomerase inhibitors, Prodrugs

Status

Grant

Latest ANP Technologies News

ANP’s Polymeric Drug Excipient Drug Master File (DMF) Accepted and Published by the U.S. Food and Drug Administration (FDA)

Jun 3, 2022

Search jobs 02-Jun-2022 ANP’s Polymeric Drug Excipient Drug Master File (DMF) Accepted and Published by the U.S. Food and Drug Administration (FDA) NEWARK, Del.--(BUSINESS WIRE)--ANP Technologies, Inc. ( ANP ) announced that its drug master file (DMF) on its novel, nano-encapsulating polymer-based drug excipient, ANP001B has been accepted and published by the U.S. Food & Drug Administration (FDA). The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform that can be broadly applicable for many active pharmaceutical ingredients (API’s) – particularly those that are poorly soluble, need better pharmacokinetics, improved safety or tolerability, enhanced biodistribution or those requiring targeted delivery. The novel nano-encapsulating polymer, ANP001B, is a proprietary polymer composition developed by ANP and has been successfully used in the chemotherapy drug, FID-007 during the clinical trial conducted by ANP and its Partner Fulgent Pharma for the treatment of solid tumors in pre-treated cancer patients. The clinical trial was performed at the University of Southern California (USC) Norris Comprehensive Cancer Center and the results were published in 2021 at the American Society of Clinical Oncology (ASCO) Annual Meeting ( ASCO FID-007 ). “This is a significant validation and confirmation of ANP’s nano-encapsulating polymer drug delivery platform,” said Dr. Ray Yin, President, and CTO of ANP. “Based on the data from the clinical trial, ANP001B is safe for intravenous (IV) injection in humans. In addition to FID-007, we are also working on a number of other drug candidates using the same nano-drug delivery platform with the goal to provide next generation formulation solutions by tackling age old problems associated with poor solubility, efficacy and tolerability. Our strong intellectual property (IP) position and low-cost manufacturing advantages have uniquely positioned ANP within the highly competitive drug development field, as it allows the rapid and vertical integration of our nano-drug delivery platform with various APIs seamlessly.” About ANP Technologies, Inc. ANP Technologies, Inc. is a clinical stage biopharmaceutical company and a world leader in developing innovative nano-therapeutics and nano-diagnostic tests. ANP has been a premier provider to supply its rapid multiplexed lateral flow tests for the detection of various biological agents to the U.S. Department of Defense in the past 15 years, as well as successfully licensed various pre-clinical and clinical stage nanotherapeutics to companies such as Celgene/BMS and Fulgent Pharma. Visit anptinc.com for more information. Contacts

ANP Technologies Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ANP Technologies Rank

  • When was ANP Technologies founded?

    ANP Technologies was founded in 2002.

  • Where is ANP Technologies's headquarters?

    ANP Technologies's headquarters is located at 824 Interchange Blvd., Newark.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.